18F-AV-45 Amyloid PET Imaging in Primary Progressive Aphasia - Florbetapir Amyloid PET Imaging in Focal Dementia Syndromes

Avid Radiopharmaceuticals, Inc.0 sites23 target enrollmentAugust 1, 2011

Overview

No summary available.

Registry

who.int

Start Date

August 1, 2011

End Date

July 19, 2013

Last Updated

6 years ago

Study Type

Interventional clinical trial of medicinal product

Sponsor

•1\. Are currently enrolled in the longitudinal study of frontotemporal lobular degeneration at the Dementia Research Centre (DRC) at UCL
•2\. Patients with PPA will have undergone detailed neuropsychological assessments and will be classified in one of three syndromic groups:PNFA, LPA, or SD
•3\. Can tolerate a PET scan procedure
•PCA\-AD Group
•1\. Are currently enrolled in the longitudinal study of frontotemporal lobular degeneration at the Dementia Research Centre (DRC)
•2\. Patients with PCA\-AD will have undergone detailed neurological assessments and will fulfil the following criteria: 1\) insidious onset of cognitive decline, sufficient to interfere with activities of daily living, with absence of structural lesion or significant whilte matter disease on MRI. 2\) relatively preserved episodic memory; deficits on standard psychological testing in at least two of four posterior cortical functions: (a) object perception (b) space perception (c) calculation (d) spelling
•3\. can tolerate a PET scan procedure
•Cognitively normal group
•1\. have no cognition complaints
•2\. are between 55 and 90 years of age

•1\. Have clinically significant hepatic, renal, pulmonary, metabolic, or endocrine disturbances
•2\. Have a clinically significant cardiovascular disease
•3\. Have a clinically significant infectious disease
•4\. Have a history of alcohol or substance abuse or dependence
•5\. Have a history of severe drug allergy or hypersensitivity
•6\. Women of child bearing potential